Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 199 clinical trials
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy …

  • 0 views
  • 24 Oct, 2022
  • 90 locations
A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants

platinum-based chemotherapy
cancer chemotherapy
atezolizumab
pemetrexed
measurable disease
  • 0 views
  • 20 Oct, 2022
  • 23 locations
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) (POD1UM-204)

platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.

cancer
platinum-based chemotherapy
metastatic endometrial cancer
  • 90 views
  • 25 Oct, 2022
  • 56 locations
International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy (ICON9)

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based

recurrent disease
bevacizumab
cancer of the ovary
parp inhibitor
tumor debulking
  • 416 views
  • 11 Oct, 2022
  • 52 locations
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) (DUO-E)

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for

recurrent disease
olaparib
platinum-based chemotherapy
sarcoma
durvalumab
  • 112 views
  • 25 Oct, 2022
  • 19 locations
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NIVOTHYM)

platinum-based chemotherapy.

liver metastasis
platelet count
thymic neoplasm
thymic carcinoma
metastasis
  • 183 views
  • 04 Oct, 2022
  • 14 locations
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer (PARTNER)

platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

triple negative breast cancer
EGFR
paclitaxel
invasive breast cancer
carboplatin
  • 17 views
  • 29 Jan, 2022
  • 1 location
  • 1 views
  • 21 Oct, 2022
  • 47 locations
Platino-resistance in Ovarian Cancer (PlatinOv)

Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive

ascites
ovarian cancer
  • 0 views
  • 04 Oct, 2022
  • 1 location
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (EVOKE-01)

(NSCLC) with progression on or after platinum-based chemotherapy and anti-programmed death protein 1 (PD-1)/ programmed death ligand 1 (PD-L1) immunotherapy received either in combination or sequentially

kinase inhibitor
platinum-based chemotherapy
tyrosine
cancer chemotherapy
EGFR
  • 1 views
  • 18 Oct, 2022
  • 118 locations